Clinical trials: Glomerulonephritis
Lupus Nephritis
Safety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy Trial
This is a Phase IV, open-label, randomized trial to determine whether the combination of Belimumab (BEL) and Voclosporin (VCS), plus background therapy with Mycophenolate Mofetil (MMF), improves the proportion of patients with…
- Trial name
- SYNERGY (NCT07225387)
- Testing
- Voclosporin
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- NephroNet, Inc.
Lupus Nephritis
A Multicenter Phase 2a Clinical Study to Evaluate SIM0278 in Subjects With Active Lupus Nephritis
This is a randomized, double-blind, placebo-controlled multicenter clinical study to evaluate the efficacy, safety, and pharmacokinetics of SIM0278 in adult (18-75 years) subjects with active LN suitable for systemic therapy.
- Trial name
- NCT07393451
- Testing
- SIM0278 injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Simcere Pharmaceutical Co., Ltd
C3 Glomerulonephritis, C3 Glomerulopathy
Non-contrast Enhanced MRI in Patients With C3 Glomerulopathy (C3G) or Immune-complex Membranoproliferative Glomerulonephritis (IC-MPGN) Enrolled in the ACH471-205 Study
Functional and quantitative renal magnetic resonance imaging (MRI) has seen a number of recent advances, and techniques are now available that can generate quantitative imaging biomarkers with the potential to improve the…
- Conditions
- C3 Glomerulonephritis, C3 Glomerulopathy, Immune Complex Membranoproliferative Glomerulonephritis, IC-MPGN
- Trial name
- NCT03723512
- Testing
- Non contrast-enhanced magnetic resonance imaging
- Where
- Italy
- Volunteers
- 7 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Glomerulonephritis, Membranous
Treatment of Patients With Idiopathic Membranous Nephropathy
Patients with idiopathic membranous nephropathy at risk for renal failure can be identified in an early stage by measuring urinary low molecular weight proteins and urinary immunoglobulin G (IgG).
- Trial name
- NCT00135954
- Testing
- Cyclophosphamide and steroids
- Where
- Netherlands
- Volunteers
- 29 people
- Sponsor
- Radboud University Medical Center
Glomerulonephritis, Membranoproliferative
Pilot Study of Rituximab for Membranoproliferative Glomerulonephritis
Membranoproliferative glomerulonephritis (MPGN) is a relatively-rare, immune-mediated kidney disease. All current therapies are inadequate and MPGN frequently leads to kidney failure.
- Trial name
- NCT00275613
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Mayo Clinic
Lupus Nephritis
An Efficacy and Safety Study of CNTO 136 in Patients With Active Lupus Nephritis
The purpose of this study is to evaluate the efficacy and safety of CNTO 136 administered intravenously in patients with active, International Society of Nephrology/Renal Pathology Society Class III and IV Lupus Nephritis (LN).
- Trial name
- NCT01273389
- Testing
- CNTO 136
- Where
- 21 sites in United States, Belgium and 4 more
- Volunteers
- 25 people
- Sponsor
- Janssen Research & Development, LLC
Idiopathic Membranous Nephropathy
Treatment of Idiopathic Membranous Nephropathy With Tripterygium Wilfordii Plus Steroid vs Tacrolimus Plus Steroid
The purpose of this study is: To explore the potential role of Tripterygium wilfordii plus steroid in the treatment of membranous nephropathy. To investigate the safety and tolerability of Tripterygium wilfordii plus steroid
- Trial name
- NCT01161459
- Testing
- Tripterygium wilfordii, FK506
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Zhi-Hong Liu, M.D.
IgA Nephropathy
Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (IgAN)
A multi-center, randomized, controlled clinical trial to evaluate the short-term and long-term efficacy and safety of mycophenolate mofetil (MMF) in reducing proteinuria and preserving renal function in patients with IgAN who…
- Trial name
- NCT00657059
- Testing
- irbesartan, methylprednisolone (MP) or prednisone (pred), mycophenolate mofetil (MMF)
- Where
- China
- Volunteers
- 151 people
- Sponsor
- Sun Yat-sen University
Humoral Rejection, Guillain-Barre Syndrome
Changes in Haemostasis After Therapeutic Plasmapheresis With Citrate Anticoagulation
Plasma exchange procedures remove procoagulant and anticoagulant factors. Every procedure increases the risk of bleeding and repeated procedures increase the risk of bleeding mostly because lower fibrinogen levels.
- Conditions
- Humoral Rejection, Guillain-Barre Syndrome, Miller Fisher Syndrome, CIDP
- Trial name
- NCT03801135
- Testing
- Fibrinogen concentrate, Fresh Frozen Plasma
- Where
- Slovenia
- Volunteers
- 20 people
- Sponsor
- University Medical Centre Ljubljana
IgA Nephropathy, Focal Segmental Glomerulosclerosis
A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects
The purpose of this first in human study is to evaluate the safety, tolerability, pharmacokinetics (PK),and pharmacodynamics (PD) of HS-10390 in healthy subjects.
- Trial name
- NCT05942625
- Testing
- HS-10390 tablet
- Where
- China
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Hansoh BioMedical R&D Company
Lupus Nephritis
Per-protocol Repeat Kidney Biopsy in Incident Cases of Lupus Nephritis
Lupus nephritis (LN) is one of the most severe complications of systemic lupus erythematosus (SLE). Among people living with SLE, 35-60% will develop LN during the course of the disease.
- Trial name
- REBIOLUP (NCT04449991)
- Testing
- Repeat kidney biopsy
- Where
- Sweden
- Volunteers
- 206 people
- Sponsor
- Karolinska Institutet
Lupus Nephritis
Human Umbilical Cord Mesenchymal Stem Cells Treatment for Lupus Nephritis (LN)
Lupus nephritis (LN) is one of the most serious complications and the main cause of death in patients with systemic lupus erythematosus (SLE).The investigators have investigated the usefulness, and confirmed the efficacy and…
- Trial name
- NCT03580291
- Testing
- Mesenchymal stem cells, Mycophenolate Mofetil
- Where
- China
- Volunteers
- 230 people
- Sponsor
- Lingyun Sun
Fibrillary Glomerulonephritis
Two Anti-CD20 Regimens for Fibrillary Glomerulonephritis
This study aims to evaluate the clinical and histological effects of two rituximab-based regimens in fibrillary glomerulonephritis.
- Trial name
- CD20FG (NCT06680349)
- Testing
- Anti-CD20 antibodies
- Where
- Italy
- Volunteers
- 21 people
- Sponsor
- University of Turin, Italy
C3 Glomerulonephritis, Dense Deposit Disease
A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN
The primary objective of this study was to determine whether ACH-0144471 (also known as danicopan and ALXN2040) increases blood C3 complement protein (C3) levels in participants with low C3 levels due to either C3G or IC-MPGN.
- Conditions
- C3 Glomerulonephritis, Dense Deposit Disease, C3 Glomerulopathy, Immune Complex Mediated Membranoproliferative Glomerulonephritis
- Trial name
- NCT03124368
- Testing
- Danicopan
- Where
- 3 sites in Australia, Belgium and 1 more
- Volunteers
- 6 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
IgA Nephropathy (IgAN), Berger Disease
A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN)
The purpose of this study is to evaluate the effect of cemdisiran on proteinuria in adults with immunoglobulin A nephropathy (IgAN), who excrete >1 gram (gm) of protein per day despite standard of care, which includes treatment…
- Conditions
- IgA Nephropathy (IgAN), Berger Disease, Glomerulonephritis, IgA
- Trial name
- NCT03841448
- Testing
- Cemdisiran
- Where
- 17 sites in Canada, France and 7 more
- Volunteers
- 31 people
- Sponsor
- Alnylam Pharmaceuticals
Proteinuria, Immunoglobulin A (IgA) Nephropathy
Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis
To evaluate the safety and efficacy of sparsentan tablets for the treatment of patients with proteinuria after kidney transplantation with once-daily dosing for 36 weeks.
- Conditions
- Proteinuria, Immunoglobulin A (IgA) Nephropathy, Focal Segmental Glomerulosclerosis, Kidney Transplant
- Trial name
- SPARX (NCT07219121)
- Testing
- Sparsentan
- Where
- 8 sites in United States
- Volunteers
- 20 people
- Sponsor
- Travere Therapeutics, Inc.
Lupus Nephritis
Renal Arterial Resistive Index as a Noninvasive Biomarker of Disease Activity in Lupus Nephritis Patients
Systemic Lupus Erthymatosous (SLE) is achronic inflammatory multi system auto immue disease characterized by pathogenic auto anti bodies production against nuclear structures (Bolouri et al.,2022), SLE affecting mainly woemn of…
- Trial name
- NCT06631404
- Testing
- renal doppler
- Where
- Egypt
- Volunteers
- 55 people
- Sponsor
- Sohag University
IgA Nephropathy
Phase 2b Open-Label Repeat Kidney Biopsy Study
Assess impact of sibeprenlimab on IgA deposition and other histological endpoints in kidney tissue at Week 52 relative to baseline
- Trial name
- NCT06740526
- Testing
- Sibeprenlimab
- Where
- 19 sites in United States, Argentina and 3 more
- Volunteers
- 56 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Lupus Nephritis
Aurinia Renal Response in Active Lupus With Voclosporin
The purpose of this study is to assess the efficacy of voclosporin compared with placebo in achieving renal response after 52 weeks of therapy in subjects with active lupus nephritis.
- Trial name
- AURORA (NCT03021499)
- Testing
- Voclosporin
- Where
- 185 sites in United States, Argentina and 29 more
- Volunteers
- 358 people
- Sponsor
- Aurinia Pharmaceuticals Inc.
IgA Nephropathy
Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy
This study is a multicenter, randomized phase II clinical study to evaluate Efficacy and safety, while observing pharmacokinetic profiles, pharmacodynamic effects, and immunogenicity of CM338 in subjects with Immunoglobulin…
- Trial name
- NCT05775042
- Testing
- CM338
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Keymed Biosciences Co.Ltd